Nyxoah (NYXH) Q3 2026 Earnings Call Transcript

Nyxoah reported Q3 2026 revenue of EUR 9.2 million, up 365% year over year and 19% sequentially, while gross margin rose to 63.1% from 60.5% and operating loss narrowed to EUR 21.9 million from EUR 24.4 million. The company lowered its 2026 revenue guidance to EUR 33 million–EUR 35 million; cash and financial assets totaled EUR 77.1 million at Sept. 30, down EUR 20.7 million from June 30. Management cited 342 surgeons trained, 233 active accounts, and a 447-patient prior-authorization pipeline, and said it submitted an FDA supplement seeking to expand Genio's indication to complete concentric collapse patients.

Analysis

The key underwriting issue is conversion, not reach: trained surgeons, new accounts and the authorization queue have value only if they translate into completed procedures and repeat utilization. The missing data are account-level procedure volumes, authorization-to-implant conversion, and time from evaluation to procedure; without them, the launch funnel cannot yet validate management’s adoption narrative. The guidance reset raises the bar for credibility, while higher commercial spending and cash use make execution errors more costly. Gross-margin expansion is encouraging but appears volume-dependent, so a slower ramp could reverse the leverage.

Over the next 1–3 months, focus on Q4 delivery versus the revised range and any first 2027 outlook; another shortfall would likely pressure the launch multiple. Over 6–18 months, FDA review of the CCC supplement is an asymmetric catalyst, but the cited share of patients evaluated is not equivalent to an addressable, reimbursed population or near-term revenue. Higher CMS facility rates may help provider economics, but do not by themselves establish improved company pricing or procedure conversion. A potential beneficiary is the broader HGNS category if a second offering expands referrals; that could also intensify competition with unilateral-system providers such as Inspire Medical Systems. Contrarian point: adoption friction may be normal for a new procedure, but the quarter’s funnel metrics do not yet prove it is temporary.

Key Decisions for Investors

• Keep NYXH on a catalyst watchlist rather than adding on launch claims alone. Before upgrading, verify U.S. procedure growth, authorization-to-procedure conversion, and utilization per active account in the next report.
• Treat the CCC supplement as a conditional upside catalyst, not base-case value: confirm FDA review progress and any subsequent evidence on real-world outcomes and payer access. A delay, restrictive label, or weaker-than-study performance would falsify the expansion thesis.
• Monitor liquidity alongside growth: reconcile quarterly cash and financial-asset movements with operating cash flow and expected commercial investment. A further material deterioration without faster revenue conversion would weaken the risk/reward.
• Reassess after Q4 results and 2027 guidance. Delivery within the revised 2026 range plus improving procedure conversion would support reconsideration; another miss or no evidence of deeper account utilization argues against a long position.